JPRN-jRCT2031230123
Active, not recruiting
Phase 2
An Open Label Study Assessing the Safety and Tolerability of SB206 in Japanese subjects with Molluscum Contagiosum
Yoshiyuki Kaneko0 sites20 target enrollmentJune 8, 2023
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Yoshiyuki Kaneko
- Enrollment
- 20
- Status
- Active, not recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Japanese patients with molluscum contagiosum aged 2 years or older and in good general health;
- •\- Patients who are able to understand and follow study instructions or who have support from the parent or legal guardian;
- •\- Patients who have a documented informed consent from voluntary signed by subject or a representative (parent or legal guardian) who received full explanations regarding the objectives and details of the study and the study drug.
Exclusion Criteria
- •\- Patients who have molluscum contagiosum only in periocular area;
- •\- Patients who have received any treatment for molluscum contagiosum during the 14 days prior to Baseline;
- •\- Patients who are suspected to be immunosuppressed or have immunodeficiency disorder, or are on immunosuppressive treatment;
- •\- Patients who have history or presence of clinically significant medical, psychiatric, or emotional condition that, in opinion of the investigator, would compromise the safety of the subject or the quality of the data.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Open-Label Safety Study of MF/F in AsthmaPersistent AsthmaTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2014-004583-38-Outside-EU/EEASchering-Plough Research Institute, a division of Schering Corporation49
Completed
Phase 1
Thorough QT/QTc Study of S-600918 in Healthy Adult ParticipantsJPRN-jRCT2080225293SHIONOGI & CO., LTD.40
Active, not recruiting
Not Applicable
The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in CanadaEUCTR2015-003491-69-Outside-EU/EEAovartis Pharmaceuticals4
Completed
Not Applicable
A Study of Once-Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Pre-Dialysis Patients Not Currently Treated With ESA.-D638 Anaemia in other chronic diseases classified elsewhereAnaemia in other chronic diseases classified elsewhereD638PER-041-08PRODUCTOS ROCHE Q.F.S.A.,
Completed
Phase 1
An Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Dapagliflozin 70 mg Extended Release Capsules in Healthy VolunteersACTRN12620001187932ovotech (Australia) Pty Limited10